Getz Healthcare Australia has announced a strategic partnership with IGEA Medical to introduce the Cliniporator VITAE, an advanced reversible electroporation technology, to healthcare providers across Australia. Following its successful launch in New Zealand, this collaboration marks a major milestone in expanding access to innovative treatments for cancer and vascular malformations in the region.
Developed by IGEA Medical, the Cliniporator VITAE is a state-of-the-art system designed to enhance the delivery of chemotherapy using adaptive reversible electroporation technology. By generating precise electrical pulses, it boosts the absorption of chemotherapy drugs into cancer cells. This minimally invasive and highly targeted approach opens new possibilities for improving cancer care and treating vascular malformations, providing healthcare professionals with a powerful tool to achieve better patient outcomes.
This partnership highlights Getz Healthcare’s commitment to advancing medical innovation. By introducing the Cliniporator VITAE in Australia, the company empowers clinicians with cutting-edge technology to deliver superior care and explore new therapeutic possibilities.
Derek Foltin, Managing Director of Getz Healthcare Australia & New Zealand, expressed his enthusiasm: “This partnership represents a significant milestone in our mission to deliver transformative healthcare solutions across the Asia-Pacific region. Our goal is to revolutionize cancer and vascular malformation treatments in Australia by equipping clinicians with this cutting-edge electroporation technology. We are excited about the positive impact this will have on patient care and look forward to strengthening our collaboration with IGEA to drive further advancements in the region.”